Full text is available at the source.
Abstract
In 2022, antibodies against non-junctional claudin-1 were produced, showing potential to attenuate hepatic fibrosis.
- Claudins are key components of tight junctions between epithelial cells and play roles in drug absorption.
- Disruption of claudin-based seals is often linked to inflammation in various diseases.
- Junctional claudin modulators have been developed to address inflammatory diseases.
- Recent advances suggest a shift in focus from claudins' barrier functions to their roles in cellular signaling.
- Claudins may serve as drug targets related to fibrosis, autophagy, and metabolism.
Simplified